Merck

Detecting & Removing Aggregates

Biological products such as monoclonal antibodies (mAbs) are prone to protein aggregation during production. Aggregation leads to challenges in the production environment, impacting the efficiency of purification operations. More importantly, it can lead to drug safety concerns for patients; high levels of aggregates can over-stimulate the patient’s immune system, resulting in adverse responses. For these reasons, the aggregate level in drug products is considered a critical quality attribute, and aggregate control throughout both upstream and downstream processing is a focus area for biomanufacturers. 

Aggregates are formed by association of multiple protein molecules (multimers) held together permanently or reversibly. They range from as few as two to many associated protein molecules.

Aggregate control starts with clone selection upstream and continues downstream with careful control of elution from capture chromatography and incubation in low pH viral inactivation steps. Excipients and stabilizers can be used to minimize aggregate formation while chromatographic steps downstream are used for efficient aggregate removal. The efficiency of some downstream operations such as virus filtration can be significantly impacted by the presence of aggregates, and adsorptive prefiltration is often used to minimize batch-to-batch variability and enhance process robustness.  

Approaches to minimize aggregate formation include:

  • Molecule and cell line manipulation
  • Careful selection of process consumables and excipients
  • Optimization and control of process parameters

Minimizing aggregates improves process efficiency, at a time when flexibility and speed to market are increasingly important.



Related Webinars

Shows an abstract human figure interacting with a colorful display on a laptop, symbolizing the modern digital interaction between humans and various interfaces.
Product Aggregation in Bioprocessing: Origins, Prevention, and Removal

Biological product aggregates form within a bioprocessing environment, based on process conditions and biochemistry, and how these are detected.

Shows an abstract human figure interacting with a colorful display on a laptop, symbolizing the modern digital interaction between humans and various interfaces.
IEX Chromatography: How to Get the Most out of Your mAb Process

Antibody aggregate removal can be significantly improved through CEX if the monomeric forms elutes before the aggregates come off the column.

Shows an abstract human figure interacting with a colorful display on a laptop, symbolizing the modern digital interaction between humans and various interfaces.
Optimizing viral clearance filtration with prefilters

Learn how prefiltration technologies can provide significant increases in the performance of your viral clearance filter.



      Workflow

      The image depicts a modern laboratory with scientists in lab

      Monoclonal Antibody Manufacturing

      Increased process understanding has led to advancements in mAb manufacturing that include efficiencies in both upstream and downstream processing

      A purple line art design featuring a circular pattern with symmetrical elements that resemble cell line development.

      The upstream process begins with cell line development and includes all steps up to cell harvest, with the goal of increasing cell densities and product titers to maximize mAb production 

      A purple line drawing of a traditional printing press, depicting quikscale® scalable family of columns

      From cell harvest through final filling into vials, the comprehensive focus of downstream bioprocessing is on purification while controlling bioburden and assuring viral safety, in order to provide confidence in drug safety for patients

      A purple line drawing of a conveyor belt carrying three bottles, with arrows indicating motion from left to right.

      Final filling of drug products must meet stringent requirements for sterility, integrity, cleanliness, operational safety, and efficiency 

      A purple outline of a gas cylinder with a grid pattern in the middle, featuring two valves at the top and a flat base.

      Based on the principles of “prevent, detect, and remove,” viral safety combines risk analysis with careful selection of raw materials, extensive testing of raw materials and process intermediates, and implementation of virus reduction steps in downstream processing

      A purple line drawing of a syringe and a vaccine vial, depicting the syringe with its needle pointed upwards and the vial with a cap on top, both illustrated in a simplified style focusing on their basic shapes and structures.

      All mAb production processes are at risk for microbial contamination, requiring a process design with control strategies to mitigate the risk, as well as bioburden monitoring to assure process control


      Sign In To Continue

      To continue reading please sign in or create an account.

      Don't Have An Account?